Future Perspectives: Key Trends Shaping the Losartan Market Up to 2030

The losartan market is set to experience consistent growth through 2030, driven by various healthcare trends and demographic changes. With increasing awareness of cardiovascular health and expanding access to medication, this market is poised for notable expansion in the coming years. Here is a detailed analysis of the market size, key players, trends, and segmentation.

Long-Term Growth Expectations for the Losartan Market Size Until 2030
The losartan market is projected to steadily increase, reaching a valuation of $1.83 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 4.3%. Several factors contribute to this upward trajectory, including the growing elderly population, heightened demand for kidney-protective antihypertensive medications, broader availability of affordable generic options, and a stronger emphasis on stroke prevention. Additionally, increased healthcare spending on managing chronic diseases supports this expansion. During the forecast period, significant trends include a rising prevalence of hypertension and cardiovascular disorders, a preference shift towards angiotensin receptor blockers (ARBs) instead of ACE inhibitors, increased prescriptions of generic losartan, greater application in diabetic nephropathy treatment, and broader adoption of long-term blood pressure control therapies.

Download a free report of the losartan market report:
https://www.thebusinessresearchcompany.com/report/losartan-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Top Players Dominating the Losartan Market Landscape
The losartan market comprises numerous influential pharmaceutical companies that play a pivotal role in its development and distribution. Key market leaders include Viatris Inc., Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Vasudha Pharma Chem Ltd., Unichem Laboratories Ltd., Global Pharma Tek, Manus Aktteva Biopharma LLP, Emcure Pharmaceuticals Ltd., Wellona Pharma, and JPM Pharma & Chemicals Pvt. Ltd.

Strategic Collaborations Enhancing Losartan Product Availability
In April 2025, Scienture Holdings, Inc., a US-based manufacturer specializing in losartan, formed a partnership with Saptalis Pharmaceuticals to produce Arbli, a losartan potassium oral suspension (10 mg/mL). This collaboration encompasses warehousing and distribution agreements with strategic partners to ensure the product's readiness for the market. Arbli stands out as the first FDA-approved ready-to-use oral liquid losartan, addressing a significant unmet need in hypertension treatment. Saptalis Pharmaceuticals, also based in the US, brings expertise in pharmaceutical manufacturing to this venture.

View the full losartan market report:
https://www.thebusinessresearchcompany.com/report/losartan-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Fueling Growth in the Losartan Market
The losartan market is benefitting from several key trends that are positively influencing its growth. One notable development is the increasing use of losartan in managing diabetic nephropathy, a common complication among diabetes patients. Furthermore, there is a growing preference for ARBs like losartan over ACE inhibitors due to their favorable side effect profiles, which is driving demand. The expansion of generic losartan prescriptions also makes this medication more accessible and affordable, further boosting market growth.

Innovations in Related Medical Technologies Supporting Market Expansion
In addition to pharmaceutical trends, advancements in medical devices are creating a supportive environment for treatments involving losartan. For example, companies in the portable transcranial stimulation device market are developing user-friendly, non-invasive devices such as transcranial direct current stimulation (tDCS) tools. These devices aid in managing neurological and psychiatric conditions and enhance therapy adherence. In October 2023, Finland-based medical device firm Sooma Oy launched Sooma Duo, a portable tDCS device designed for clinician-prescribed neuromodulation therapies, offering features like remote monitoring and automatic resistance control. Such innovations improve treatment outcomes and accessibility and reflect the broader movement toward integrated healthcare solutions.

Detailed Segmentation of the Losartan Market
The losartan market is categorized systematically to provide a clear understanding of its components:
1) Dosage Form: Tablet, Powder, Suspension
2) Source: Contract Manufacturing Organizations (CMOs), In-House Production
3) Distribution Channel: Online, Offline
4) Application Area: Hypertension, Stroke, Diabetic Nephropathy, Other Uses
5) End-User Group: Adult, Pediatric

The dosage forms are further broken down as follows:
- Tablets available in 25 mg, 50 mg, and 100 mg strengths
- Powders also available in 25 mg, 50 mg, and 100 mg formulations
- Suspensions offered in 5 mg per 5 mL, 10 mg per 5 mL, and 25 mg per 5 mL concentrations

This thorough segmentation helps to identify and target specific market needs and consumer groups effectively.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.